Table 2 Summary of all crystal structures of MLKL pseudokinase domain to date

From: Phosphorylation-dependent pseudokinase domain dimerization drives full-length MLKL oligomerization

PDB

Species

Variant

Ligand

Residue range

Space groupa

Conformation

Reference

Salt bridge (VAIK-αC)

R-spine

DFG

4MWI

Human

190–471

C 2 2 21

Yes

Yes

In

42

8SLZ

Human

pT357/pTS358

190–471

C 2 2 21

Yes

Yes

In

This study

4M67

Human

179–471

C 2 2 21

Yes

Yes

In

54

6LK6

Human

T357A/S358A

179–471

C 2 2 21

Yes

Yes

In

52

6LK5

Human

T357E/S358D

179–471

C 2 2 21

Yes

Yes

In

52

6BWK

Human

T357E/S358E

190–471

C 2 2 21

Yes

Yes

In

40

5KO1

Human

Compound 4

(Type I inhibitor)

191–471

C 2 2 21

Yes

Yes

In

55

5KNJ

Human

Compound 1

(Type II inhibitor)

191–471

P 21 21 21

Yes

No

Out

55

6O5Z

Human

Compound 2

(Type II inhibitor)

190–471

P 21

Yes

No

Out

56

7JW7

Human

Mb27 (protein)

190–471

P 31 2 1

Yes

Yes

In

33

7JXU

Human

Mb32 (protein)

190–471

P 43

No

No

In

33

7MON

Human

RIPK3 (protein)

190–471

P 21 21 21

No

No

In

29

4BTF

Mouse

1–464

P 21 21 21

No

No

In

32

4M69

Mouse

RIPK3 (protein)

182–464

C 2 2 21

No

No

Out

54

4M68

Mouse

182–464

P 21

No

No

In

54

6VC0

Horse

188–475

C 2

Yes

Yes

In

36

6VBZ

Rat

179–464

P 61 2 2

Yes

Yes

In

36

  1. aDetails of unit cell dimensions are provided in Supplementary Table 3.